November is designated as Pancreatic Cancer Awareness Month, a time to raise awareness and promote education, prevention and treatment for the disease that has one of the lowest survival rates of all known cancers.
Treatment for pancreatic cancer can be a curative or palliative approach involving surgery, radiation therapy, chemotherapy or a combination of these treatments.
Because there is currently no known reliable method of early detection for pancreatic cancer, 53 percent of cases are diagnosed after the cancer has spread, or metastasized, to other organs in the body. This high rate of metastasis disqualifies about 80 percent of patients for surgery to remove the cancer.
For these patients with advanced disease who are not candidates for surgery, Rush Radiosurgery offers a specialized type of radiation therapy called stereotactic body radiation therapy (SBRT). The treatment may extend survival and/or relieve symptoms in many patients.
TrueBeam™ STx is an advanced radiosurgery system that delivers SBRT by targeting tumors with precisely focused high-dose radiation. By shaping the radiation beams to match the size and shape of the tumor site, treatment with TrueBeam STx reduces radiation exposure to surrounding healthy tissue and minimizes risks of side effects.
If you or a loved one has been diagnosed with pancreatic cancer, you can find more information on treatment with TrueBeam STx by visiting our conditions treated page here. If you’re looking for support, research or other resources, visit the Pancreatic Cancer Action Network’s website here.
This is not intended as medical advice to replace the expertise and judgment of your health care team. It is intended to help you and your family make informed decisions, together with your doctor.